Topics included:
- Overview of the Decision: What the Court Actually Said
- What Is Permitted Now
- What Must Be Disclosed
- What Has Changed: Types of Communications That May Be Paid with Corporate Funds:
- Expenditures by For-Profit Corporations
- Contributions to Advocacy Organizations
- Unenforceability of FEC Regulations prohibiting Corporate Communications With Employees & Vendors
- Types of Communications Now Permitted
- Expenditures by Nonprofit Corporations & Labor Unions
- Candidate -related expenditures – express advocacy / electioneering communications
- Unenforceability of FEC Regulations Prohibiting Voter Guides & Voting Records
- Membership communications — Protected & Enlarged
- Expenditures by For-Profit Corporations
- What Has NOT Changed:
- Disclaimer Requirements
- Donor Disclosure Requirements
- Contribution And Other Limits Unchanged
- Other Cases changing the Paradigm: SpeechNOW & Emily’s List
- Impact on State Laws Prohibiting Corporate Expenditures:
- Unenforceability of State Laws Prohibiting Corporate Expenditures Related to Candidates / Electioneering Prohibitions
- Review of tax treatment of the advocacy communications addressed in Citizens United and related political and lobbying communications and activities.
- For-profit companies
- Nonprofit advocacy organizations (501(c)(4))
- Nonprofit educational and charitable organizations ((501(c)(3))
- PAC’s, campaign committees, and other 527 organizations
- Impact of Citizens United on tax rules
- Direct impact (limited)
- Indirect impact (could be substantial)
- IRS tax enforcement in light of Citizens United
For more information, please contact Elie Harris at [email protected].
Authors
Related Insights
08 December 2023
Foley Ignite
An Update on Reauthorizing the National Quantum Initiative
Signed into law in 2018, the goal of the National Quantum Initiative Act was “to accelerate quantum research and development for the economic and national security of the United States.”
08 December 2023
Innovative Technology Insights
FDA Approves Two Gene Therapies to Treat Sickle Cell Disease Including a CRISPR-Based Therapy
These new therapies harness the power of stem cells to help patients with sickle cell disease avoid vaso-oclusive events and crises.
08 December 2023
Foley Ignite
2024 Predictions: Unveiling the future of healthcare mergers and acquisitions
Foley & Lardner's Nathaniel Lacktman and Louis Lehot discuss which categories of digital health hold the most potential for M&As and why.